Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor

ACS Medicinal Chemistry Letters

Volumn 1, Issue 8, 2010, Pages 406-410

  Garbaccio, Robert M ^a   Brnardic, Edward J ^a   Fraley, Mark E ^a   Hartman, George D ^a   Hutson, Pete H ^a   O'Brien, Julie A ^a   Magliaro, Brian C ^a   Uslaner, Jason M ^a   Huszar, Sarah L ^a   Fillgrove, Kerry L ^a   Small, James H ^a   Tang, Cuyue ^a   Kuo, Yuhsin ^a   Jacobson, Marlene A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

allosteric modulators; GPCR; hyperlocomotion model; metabotropic glutamate 2 receptor; Oxazolobenzimidazoles; schizophrenia

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; METABOTROPIC RECEPTOR 2; OXAZOLOBENZIMIDAZOLE DERIVATIVE; TERT BUTYLPHENYLOXYMETHYLCYANOOXAZOLOBENZIMIDAZOLE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HYPERACTIVITY; IN VITRO STUDY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

RATTUS;

EID: 78649291978     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100115a     Document Type: Article

References (26)

1. Regier, D. A.; Narrow, W. E.; Rae, D. S.; Manderscheid, R. W.; Locke, B. Z.; Goodwin, F. K. The de Facto US Mental and Addictive Disorders Service System: Epidemiologic Catchment Area Prospective 1-Year Prevalence Rates of Disorders and Services Arch. Gen. Psychiatry 1993, 50, 85
2. Tandon, R.; Keshavan, M. S.; Nasrallah, H. A. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview Schizophr. Res. 2008, 100, 4
3. Tandon, R.; Keshavan, M. S.; Nasrallah, H. A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology Schizophr. Res. 2008, 102, 1
4. Murphy, B. P.; Chung, Y. C.; Park, T. W.; McGorry, P. D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review Schizophr. Res. 2006, 88, 5
5. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 2005, 353, 1209
6. Chavez-Noriega, L. E.; Schaffhauser, H.; Campbell, U. C. Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia Curr. Drug Targets: CNS Neurol. Dis. 2002, 1, 261
7. Carmell, J.; Perry, K. W.; Salhoff, C. R.; Monn, J. A.; Schoepp, D. D. The Potent, Selective mGlu2/3 Receptor Agonist LY379268 Increases Extracellular Levels of Dopamine, 3,4-Dihydroxyphenylacetic Acid, Homovanillic Acid, and 5-Hydroxyindole-3-Acetic Acid in the Medial Prefrontal Cortex of the Freely Moving Rat J. Neurochem. 2000, 75, 1147
8. Macek, T. A.; Winder, D. G.; Gereau, R. W.; Ladd, C. O.; Coon, P. J. Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapse J. Neurophysiol. 1996, 76, 3798
9. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik, A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn, J. A.; Scheopp, D. D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 2007, 13, 1102
10. Wooley, M. L.; Pemberton, D. J.; Bate, S.; Corti, C.; Jones, D. M. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity Psycopharmacology 2008, 196, 431
11. Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D. Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) J. Pharmacol. Exp. Ther. 2008, 326, 209
12. Conn, J. P.; Chirstopolous, A.; Lindsley, C. W. A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models Nat. Rev. Drug Discovery 2009, 8, 41
13. Cube, R. V.; Vernier, J. M.; Hutchinson, J. H.; Gardner, M. F.; James, J. K.; Rowe, B. A.; Schaffhauser, H.; Daggett, L.; Pinkerton, A. B. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl) propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg. Med. Chem. Lett. 2005, 14, 2389 and references therein.
14. Duplantier, A. J.; Efremov, I.; Candler, J.; Doran, A. C.; Ganong, A. H.; Haas, J. A.; Hanks, A. N.; Kraus, K. G.; Lazzaro, J. T.; Lu, J.; Maklad, N.; McCarthy, S. A.; O'Sullivan, T. J.; Rogers, B. N.; Siuciak, J. A.; Spraklin, D. K.; Zhang, L. B. 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization Bioorg. Med. Chem. Lett. 2009, 19, 2524
15. Tresadern, G.; Cid, J. M.; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; Garcia, A.; Matesanz, E.; Linares, M. L.; Oehlrich, D.; Lavreysen, H.; Biesmans, I.; Trabanco, A. A. Scaffold hopping from pyridones to imidazo [1, 2-a] pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor. Bioorg. Med. Chem. Lett. 2009, 175.
16. Fraley, M. E. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin. Ther. Pat. 2009, 19, 1259 and references therein.
17. Pin, J. P; Parmentier, M. L.; Prezeau, L. Positive Allosteric Modulators for γ-Aminobutyric AcidB Receptors Open New Routes for the Development of Drugs Targeting Family 3 G-Protein-Coupled Receptors Mol. Pharmacol. 2001, 60, 881
18. Brnardic, E. J.; Fraley, M. E.; Garbaccio, R. M.; Layton, M. E.; Sanders, J. M.; Culberson, C.; Jacobson, M. A.; Magliaro, B. C.; Hutson, P. H.; O'Brien, J. A.; Huszar, S. L.; Uslaner, J. M.; Fillgrove, K. L.; Tang, C.; Kuo, Y.; Sur, S. M.; Hartman, G. D. 3-Aryl-5-phenoxymethyl-1, 3-oxazolidin-2-ones as Positive Allosteric Modulators of mGluR2 for the Treatment of Schizophrenia: Hit-to-Lead Efforts. Bioorg. Med. Chem. Lett. 2010, 3129.
19. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615
20. Benigni, F.; Trevisan, L. Synthesis of a new nitrogenous heterocycle, 2H,3H-benzimidazo[1,2-b]oxazole Farmaco, Edizione Scientifica 1974, 12, 936
21. Bell, T. W.; Hu, L. Y.; Patel, S. V. Alkylation of heteroaryl halides by 2:1 Grignard reagent/copper(I) mixtures. Synthesis of alkylated octahydrodibenzo[b,j][1,10]phenanthrolines J. Org. Chem. 1987, 52, 3847
22. Tanaka, H.; Shishido, Y. Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tertalkyl moiety Bioorg. Med. Chem. Lett. 2007, 17, 6079
23. Pinkerton, A. B.; Vernier, J.-M.; Schaffhauser, H.; Rowe, B. A.; Campbell, U. C.; Rodriguez, D. E.; Lorrain, D. S.; Baccei, C. S.; Daggett, L. P.; Bristow, L. J. Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor J. Med. Chem. 2004, 47, 4595
24. Galici, R.; Echermendia, N. G.; Rodriguez, A. L.; Conn, J. P. A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity J. Pharmacol. Exp. Ther. 2005, 315, 1181
25. Galici, R.; Jones, C. K.; Hemstapat, K.; Nong, Y.; Echemendia, N. G.; Williams, L. C.; de Paulis, T.; Conn, J. P. Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice J. Pharmacol. Exp. Ther. 2006, 318, 173
26. Rorick-Kehn, L. M.; Johnson, B. G.; Knitowski, K. M.; Salhoff, C. R.; Witkin, J. M.; Perry, K. W.; Griffey, K. I.; Tizzano, J. P.; Monn, J. A.; McKinzie, D. L.; Schoepp, D. D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Psychopharmacology 2007, 193, 121